logo
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms

A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms

Yahoo26-07-2025
A new COVID variant known as NB.1.8.1 has made landfall in the United States. As of late May, the variant, which was first detected in China this past January, accounted for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks prior.
A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. Up until late May, only 20 NB.1.8.1 sequences had been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.)
It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2.
'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost.
Here's what to know about the newest COVID variant that's gaining traction around the world.
NB.1.8.1's mutations likely make it more transmissible.
Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO).
The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests.
Here are the signs and symptoms doctors are seeing with NB.1.8.1.
According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants.
Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said.
Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said.
There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said.
How effective are the vaccines against NB.1.8.1?
It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said.
Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added.
So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot.
Know when to treat NB.1.8.1 at home and when to go visit a doctor.
Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week.
For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset.
As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said.
Related...
RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women
COVID Cases Are Rising This Summer, But Not All The Data Shows It — Here's Why
People Are Reporting A Frightening COVID Symptom Right Now — Here's What To Know
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CDC warns travelers about chikungunya cases in China as global infections hit 240,000
CDC warns travelers about chikungunya cases in China as global infections hit 240,000

USA Today

timea minute ago

  • USA Today

CDC warns travelers about chikungunya cases in China as global infections hit 240,000

U.S. health officials are cautioning travelers about a mosquito-borne illness being transmitted in parts of Asia, South America, Africa and the Indian Ocean. Across the globe, the chikungunya virus has sparked 240,000 cases and 90 deaths in 2025, according to the European Centre for Disease Prevention and Control. The virus, which is infecting people through bites from Aedes mosquitoes, has been spreading in China's Guangdong province this summer. Health officials reported the area has seen over 7,000 confirmed cases since June. The U.S. Centers for Disease Control and Prevention (CDC) this month issued a travel notice for the Guangdon province in China, encouraging travelers to practice enhanced precautions. The agency issued the same notices for other countries where outbreaks have been reported, including Bolivia, Kenya, Madagascar, Mauritius, Mayotte, Réunion, Somalia and Sri Lanka. The CDC is also asking U.S. residents to exercise caution when visiting the following countries, which have not yet reported an outbreak but are at elevated risk of exposure: Brazil, Colombia, Mexico, India, Pakistan, Philippines, Thailand and Nigeria. According to the World Health Organization (WHO), 5.6 billion people are at risk of arboviral diseases such as chikungunya. Other widespread arboviruses impacting humans include dengue, Zika and yellow fever. What are the symptoms of chikungunya? Symptoms of the disease include fever, joint pain and swelling, headache, muscle pain and rash, according to the CDC. How long does infection last? The illness typically lasts between two to 12 days after infection. Some patients can experience extreme symptoms and the virus can be fatal. Elderly people, newborns and individuals with underlying medical conditions are at higher risk of medical intervention. Severe complications, including cardiovascular, neurological and multiorgan involvement, may require intensive medical care, according to the WHO. However, more than half of patients will experience symptoms commonly associated with a fever. What treatments are available? There are no known antiviral treatments for the illness. Medications can be used to manage pain and fever. Two chikungunya vaccines have received regulatory approval but are not widely available. In May, federal officials recommended pausing a vaccine in the United States after reports of serious adverse events. The illness was first discovered in Tanzania in 1952, with outbreaks being reported in Africa and Asia, according to the WHO. Since then, the virus has been transmitted to 119 countries. Last year, more than 620,000 and 213 deaths were reported globally, according to the European Centre for Disease Prevention and Control. In what was then dubbed the largest documented outbreak of chikungunya, an estimated several hundred thousand people were affected by "explosive" outbreaks of the virus in the Indian Ocean islands and India, according to a 2008 study. It's estimated that about 60 percent of regional populations were exposed. CDC issues travel notice for Americans The CDC issued a travel warning on Friday, Aug. 1, advising U.S. residents to take enhanced precautions when traveling to China. Most of the country's cases have been reported in the city of Foshan. Last month, Chinese officials held a national conference to discuss treatments for and prevention of the illness. Authorities agreed to continue monitoring the situation and issue early warnings through multiple channels to prevent further spreading, according to China's National Health Commission. Michelle Del Rey is a trending news reporter at USA TODAY. Contact her at mdelrey@

Linda Yaccarino joins health tech platform eMed as CEO after leaving X
Linda Yaccarino joins health tech platform eMed as CEO after leaving X

TechCrunch

timea minute ago

  • TechCrunch

Linda Yaccarino joins health tech platform eMed as CEO after leaving X

Linda Yaccarino's next role after departing X as CEO will be another chief executive role at eMed Population Health, an AI startup building a tech platform for patients using GLP-1s. Yaccarino was a longtime advertising executive at NBCUniversal, but left to join X as CEO for two years, where she managed to have a positive impact on the social network's troubled ad revenue model, despite her and Elon Musk's shared approach to minimizing content moderation. Though Yaccarino does not have experience in health tech, eMed said in a press release that they sought her out for her 'undeniable ability to negotiate new partnerships' — it certainly also helps that her tenure at X made her well-known in the tech world, drawing more eyes toward the startup. eMed previously produced a tech platform that was designed to be used with at-home COVID-19 rapid antigen tests, guiding users through the process of administering these tests properly. Now, eMed is focused on GLP-1s, the class of drugs like Ozempic, which can be used for both weight management and treatment of type II diabetes. 'To be a leader in today's healthcare marketplace, companies need to have a fearless tenacity that allows them to not only grow, but to also be brave enough to step forward and redefine an entire industry,' Yaccarino said in a press release. 'We are very well-positioned to be that tenacious leader, striving toward our ultimate goal of improving global healthcare outcomes through our groundbreaking services and platforms.'

NASA wants US to be the first nation to put nuclear reactor on the moon
NASA wants US to be the first nation to put nuclear reactor on the moon

CNN

timean hour ago

  • CNN

NASA wants US to be the first nation to put nuclear reactor on the moon

Acting NASA Administrator Sean Duffy has directed the agency to fast-track plans to put a nuclear reactor on the moon. Expediting work to place a reactor on the lunar surface to help power moon exploration efforts would keep the United States ahead of China and Russia, both of which have 'announced on at least three occasions' a joint effort to develop such a project by the mid-2030s, according to a directive dated July 31 and obtained by CNN. If another country were to achieve this feat first, it could declare a 'keep-out zone' that would effectively hold the US back from its goal of establishing a presence on the lunar surface through NASA's Artemis program. The agency's Artemis III mission, currently planned for 2027, is expected to return humans to the surface of the moon for the first time in more than five decades. But the program still has several milestones in order to reach that target. 'We're in a race to the moon, in a race with China to the moon,' Duffy told reporters at a news conference Tuesday on drones. 'And to have a base on the moon, we need energy.' Duffy's orders also call for an executive within 30 days to lead the program. Politico was the first to report the new directive. NASA has previously worked on similar projects in collaboration the Department of Energy and others, including a fission surface power project that would provide the moon with at least 40 kilowatts of power — enough to continuously run 30 households for 10 years, according to the NASA website. A nuclear reactor would assist with long stays on the moon, but the newly unveiled plans do not yet specify when a base could be built. Lunar surface power needs are at least 100kWe for long-term human operations, according to estimates cited by NASA. 'Energy is important, and if we're going to be able to sustain life on the moon, to then go to Mars, this technology is critically important,' Duffy said. The directive is Duffy's first big initiative since he was named NASA's acting administrator in July, an extra job he's been criticized for accepting alongside Secretary of Transportation, an agency that has had a tumultuous year navigating aviation safety incidents. He also issued a second directive last Thursday that could accelerate efforts to create a commercial space station to replace the International Space Station. NASA will seek more proposals within 60 days, and at least two companies will be awarded a contract within six months of the agency's request for proposals, according to the directive. The order changes the way the agency awards contracts by adding some flexibility. The aging International Space Station has experienced problems with leaks in recent years and is expected to be retired by 2030.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store